博济医药(300404) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was RMB 324,202,622.53, representing a 24.47% increase compared to RMB 260,468,434.47 in 2020[19]. - The net profit attributable to shareholders in 2021 was RMB 38,882,189.38, a significant increase of 128.87% from RMB 16,988,641.81 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 25,214,668.12, up 155.84% from RMB 9,855,541.21 in 2020[19]. - The company's total assets increased by 51.84% to RMB 1,138,209,210.53 at the end of 2021, compared to RMB 749,631,868.84 at the end of 2020[19]. - The net assets attributable to shareholders rose by 83.23% to RMB 813,994,073.02 at the end of 2021, up from RMB 444,239,449.04 in 2020[19]. - The basic earnings per share for 2021 was RMB 0.1594, reflecting a 112.25% increase from RMB 0.0751 in 2020[19]. - The diluted earnings per share was RMB 0.1588, also up 112.02% from RMB 0.0749 in the previous year[19]. - The net cash flow from operating activities decreased by 68.99% to RMB 30,101,746.56 in 2021, down from RMB 97,067,618.03 in 2020[19]. - The company reported a weighted average return on equity of 6.26% for 2021, an increase of 2.32 percentage points from 3.94% in 2020[19]. Business Strategy and Expansion - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[6]. - The company aims to enhance its core competitiveness through strategic planning and leveraging its full industry chain service advantages[5]. - The company is focusing on developing innovative drug clinical services and preclinical services to mitigate risks associated with market competition[4]. - The company is committed to strengthening internal management and integrating professional management talent to improve operational efficiency[6]. - The company is focused on providing comprehensive "one-stop" CRO services, including preclinical research, clinical research, and CDMO services[36]. - The company plans to strengthen its clinical research services, particularly in liver disease, oncology, and respiratory fields, while expanding into cell and gene therapy research[110]. - The company aims to develop a comprehensive new drug research platform integrating drug research, clinical trials, and production, enhancing its competitive edge in the CRO industry[108]. - The company is actively seeking acquisition targets in niche markets to achieve rapid expansion[112]. Research and Development - The company has established six major R&D service platforms, enhancing its capabilities in traditional Chinese medicine and chemical drug research[56]. - The company has received multiple government grants for its R&D platforms, indicating strong support for its innovation efforts[57]. - The company has developed over 30 drug research projects, obtaining 3 production licenses and 5 clinical research approvals[145]. - The company has filed nearly 20 patents and published over 30 academic articles related to drug development[145]. - The company is advancing its KHK target compound screening system, which is expected to meet the demand for innovative fatty liver treatments[78]. - The company has established partnerships with various academic and research institutions to enhance innovation[145]. Market and Competition - The CRO market is projected to reach USD 64.58 billion by 2021, with a compound annual growth rate (CAGR) of 12.8% from 2016 to 2021[30]. - The Chinese CRO market is expected to grow from USD 6.8 billion in 2019 to USD 22.2 billion by 2024, with a CAGR of approximately 26.5%[31]. - The company acknowledges the increasing market competition in the CRO industry, necessitating higher marketing and service standards[5]. Governance and Compliance - The company has established and improved its governance structure in compliance with relevant laws and regulations, ensuring effective decision-making and compliance[117]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal and regulatory requirements[118]. - The company maintains independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[122]. - The company has established a complete and independent financial accounting system, ensuring independent financial decision-making[122]. - The company has not faced any penalties from regulatory bodies regarding internal control issues during the reporting period[121]. Employee and Management - The workforce increased from over 700 to approximately 1,000 employees, a growth of about 38%, with the recruitment of 9 PhDs in various fields[46]. - The total number of employees at the end of the reporting period was 989, with 384 in the parent company and 605 in major subsidiaries[165]. - The company has established a comprehensive training system to enhance employee skills and capabilities, aligning with business needs[168]. - The company has implemented a differentiated compensation policy based on department and job nature, aiming for performance-oriented salary management[167]. Financial Management - The company raised a total of CNY 343 million through the issuance of 33.45 million shares, aimed at enhancing CDMO platform construction and clinical research service capabilities[38]. - The company reported a credit impairment loss of -5,309,692.89, which accounted for -11.28% of total profit, primarily due to bad debt losses[84]. - The company has established measures to ensure the fulfillment of immediate return commitments, with legal responsibilities for any violations[200]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares and a capital reserve increase of 4 shares per 10 shares to all shareholders[6]. - The cash dividend amount for the year was CNY 5,229,363.30, representing 100% of the total profit distribution[170]. - The company plans to issue 4 new shares for every 10 shares held as part of its capital reserve conversion plan[169].